JP2015521050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015521050A5 JP2015521050A5 JP2015515598A JP2015515598A JP2015521050A5 JP 2015521050 A5 JP2015521050 A5 JP 2015521050A5 JP 2015515598 A JP2015515598 A JP 2015515598A JP 2015515598 A JP2015515598 A JP 2015515598A JP 2015521050 A5 JP2015521050 A5 JP 2015521050A5
- Authority
- JP
- Japan
- Prior art keywords
- maf
- subject
- expression level
- copy number
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261656372P | 2012-06-06 | 2012-06-06 | |
| US61/656,372 | 2012-06-06 | ||
| PCT/IB2013/001859 WO2013182912A2 (en) | 2012-06-06 | 2013-06-06 | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015521050A JP2015521050A (ja) | 2015-07-27 |
| JP2015521050A5 true JP2015521050A5 (enExample) | 2016-08-04 |
| JP6386450B2 JP6386450B2 (ja) | 2018-09-05 |
Family
ID=49237517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015515598A Active JP6386450B2 (ja) | 2012-06-06 | 2013-06-06 | 肺がん転移の診断、予後診断および処置のための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10006091B2 (enExample) |
| EP (2) | EP3467124A1 (enExample) |
| JP (1) | JP6386450B2 (enExample) |
| KR (1) | KR102226219B1 (enExample) |
| CN (1) | CN104603288B (enExample) |
| AU (2) | AU2013273242B2 (enExample) |
| BR (1) | BR112014030750A2 (enExample) |
| CA (1) | CA2875918A1 (enExample) |
| DK (1) | DK2859120T3 (enExample) |
| ES (1) | ES2705237T3 (enExample) |
| MX (1) | MX368513B (enExample) |
| TR (1) | TR201819859T4 (enExample) |
| WO (1) | WO2013182912A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3091085T3 (da) | 2010-10-06 | 2019-05-06 | Inst Catalana Recerca Estudis Avancats | Fremgangsmåde til at designe en terapi mod brystcancermetastase |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| ES2906586T3 (es) * | 2012-10-12 | 2022-04-19 | Inbiomotion Sl | Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| WO2014184679A2 (en) * | 2013-03-15 | 2014-11-20 | Inbiomotion S.L. | Method for the prognosis and treatment of renal cell carcinoma metastasis |
| KR20150122731A (ko) * | 2013-03-15 | 2015-11-02 | 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) | 암 전이의 예후 및 치료 방법 |
| WO2014140896A2 (es) | 2013-03-15 | 2014-09-18 | Fundacio Privada Institut De Recerca Biomedica | Metodo para el diagnostico, pronostico y tratamiento de la metastasis de un cancer |
| CN106795557A (zh) * | 2014-06-02 | 2017-05-31 | 瓦利保健系统公司 | 用于肺癌诊断的方法和系统 |
| CN104398506A (zh) * | 2014-12-09 | 2015-03-11 | 厦门大学 | 雷奈酸锶在制备预防和治疗腺癌药物中的新用途 |
| EP3229909B1 (en) * | 2014-12-11 | 2020-10-14 | Inbiomotion S.L. | Binding members for human c-maf |
| RU2017135072A (ru) | 2015-03-12 | 2019-04-10 | Мори Матрикс, Инк. | Применение пептидсодержащих композиций ингибитора mk2 для лечения немелкоклеточного рака легкого |
| JP6871919B2 (ja) | 2015-06-16 | 2021-05-19 | ナノファギックス エルエルシー | 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法 |
| CN105154542B (zh) * | 2015-09-01 | 2018-04-17 | 杭州源清生物科技有限公司 | 一组用于肺癌分子分型的基因及其应用 |
| EP4086285A1 (en) | 2016-02-25 | 2022-11-09 | Cell Medica Switzerland AG | Binding members to pd-l1 |
| CN109195606A (zh) * | 2016-05-13 | 2019-01-11 | 国鼎生物科技股份有限公司 | 用于治疗晚期非小细胞肺癌的方法和组合物 |
| WO2017201043A1 (en) * | 2016-05-16 | 2017-11-23 | Concert Pharmaceuticals, Inc. | Combination therapy for treating cancer |
| MX2018014279A (es) | 2016-05-25 | 2019-07-08 | Inbiomotion Sl | Tratamiento terapeutico de cancer de mama con base en estado de c-maf. |
| CN106055921A (zh) * | 2016-05-27 | 2016-10-26 | 华中农业大学 | 基于基因表达和药物靶标的药物活性预测与筛选方法 |
| CN106119405B (zh) * | 2016-08-31 | 2019-11-12 | 广州万德基因医学科技有限公司 | 一种肺癌的预后标记物、使用该标记预测肺癌预后的方法及应用 |
| CN107058480B (zh) * | 2016-12-14 | 2018-07-13 | 河北医科大学第四医院（河北省肿瘤医院） | 用于诊断肺腺癌的长链非编码rna标志物 |
| CN106815486B (zh) * | 2017-01-22 | 2021-06-04 | 华中农业大学 | 一种个性化用药的系统药理学方法 |
| CN107058499B (zh) * | 2017-01-25 | 2020-03-13 | 河北医科大学第四医院（河北省肿瘤医院） | 一种用于肺腺癌诊治的分子标志物 |
| US11654153B2 (en) | 2017-11-22 | 2023-05-23 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-MAF status |
| WO2019152788A1 (en) | 2018-02-02 | 2019-08-08 | Morgan And Mendel Genomics, Inc. | Robust genomic predictor of breast and lung cancer metastasis |
| KR102218199B1 (ko) | 2019-01-31 | 2021-02-22 | 중앙대학교 산학협력단 | 폐암 전이 예측용 바이오마커 조성물 |
| CN110157792A (zh) * | 2019-04-22 | 2019-08-23 | 中山大学孙逸仙纪念医院 | 血清外泌体has_circ_0004771在制备酒精依赖综合征诊断试剂中的应用 |
| CN110093422A (zh) * | 2019-05-24 | 2019-08-06 | 中国人民解放军西部战区总医院 | Linc02159在肺腺癌诊疗中的应用 |
| KR102260915B1 (ko) * | 2020-02-19 | 2021-06-04 | 한국원자력의학원 | 폐암의 방사선 치료 예후 예측을 위한 생체 표지자 |
| CN119143798B (zh) * | 2024-08-01 | 2025-09-30 | 河北医科大学 | 一种骨靶向阿仑膦酸-普萘洛尔及其制备方法与应用 |
| CN119876392B (zh) * | 2025-01-06 | 2025-08-12 | 上海市第六人民医院 | 一种用于辅助诊断肺腺癌骨转移的生物标志物 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE89314T1 (de) | 1985-02-13 | 1993-05-15 | Scios Nova Inc | Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| EP0910652B1 (en) | 1996-04-05 | 2014-10-08 | The Salk Institute For Biological Studies | Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| PT951551E (pt) | 1996-12-23 | 2008-10-28 | Immunex Corp | Ligando para receptor activador de nf-kb, ligando membro da superfamília de tnf |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6274338B1 (en) | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| EA200100972A1 (ru) | 1999-03-15 | 2002-02-28 | Аксис Фармасьютикалз, Инк. | Новые соединения и композиции как ингибиторы протеаз |
| TW404030B (en) | 1999-04-12 | 2000-09-01 | Siliconware Precision Industries Co Ltd | Dual-chip semiconductor package device having malposition and the manufacture method thereof |
| US6287813B1 (en) | 1999-04-23 | 2001-09-11 | Cistronics Cell Technology Gmbh | Antibiotic-based gene regulation system |
| JP2003525874A (ja) | 2000-01-06 | 2003-09-02 | メルク フロスト カナダ アンド カンパニー | プロテアーゼ阻害剤としての新規化合物および組成物 |
| WO2001098539A2 (en) | 2000-06-21 | 2001-12-27 | Hitachi Chemical Co., Ltd. | Gene markers for lung cancer |
| US6750015B2 (en) | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| CA2451955C (en) | 2001-06-26 | 2015-09-29 | Abgenix, Inc. | Antibodies to opgl |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| KR100485271B1 (ko) | 2002-01-16 | 2005-04-27 | 메타볼랩(주) | 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물 |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| DE10235624A1 (de) | 2002-08-02 | 2004-02-19 | Aventis Pharma Deutschland Gmbh | Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben |
| US20050060771A1 (en) | 2003-09-11 | 2005-03-17 | Farmer Andrew Alan | siRNA encoding constructs and methods for using the same |
| WO2005046731A1 (en) | 2003-10-17 | 2005-05-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Interference with c-maf function in multiple myeloma |
| US20090048117A1 (en) | 2003-12-18 | 2009-02-19 | President And Fellows Of Harvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| TW200526224A (en) | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| US8019552B2 (en) * | 2004-03-05 | 2011-09-13 | The Netherlands Cancer Institute | Classification of breast cancer patients using a combination of clinical criteria and informative genesets |
| WO2006012221A2 (en) | 2004-06-25 | 2006-02-02 | The Regents Of The University Of California | Target cell-specific short interfering rna and methods of use thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| US9134237B2 (en) | 2005-09-20 | 2015-09-15 | Janssen Diagnotics, LLC | High sensitivity multiparameter method for rare event analysis in a biological sample |
| JP5457673B2 (ja) | 2005-09-20 | 2014-04-02 | ベリデックス・リミテッド・ライアビリティ・カンパニー | ユニーク配列のｄｎａプローブを作製するための方法および組成物、ｄｎａプローブの標識、ならびにこれらプローブの使用 |
| US20080219996A1 (en) | 2005-09-26 | 2008-09-11 | Thea Kalebic | Molecular Markers Associated with Bone Metastasis |
| US8242081B2 (en) | 2005-12-06 | 2012-08-14 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2008098351A1 (en) | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| EP1961825A1 (en) | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
| JP2010527914A (ja) * | 2007-04-26 | 2010-08-19 | クォーク ファーマシューティカルズ インコーポレーティッド | 呼吸器系への抑制性核酸分子の治療的送達 |
| KR101264473B1 (ko) | 2007-05-24 | 2013-05-29 | 아블린쓰 엔.브이. | Ｒａｎｋ-ｌ에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드 |
| EP2211861A4 (en) | 2007-10-18 | 2010-08-25 | Univ Health Network | CLIOCHINOL FOR THE TREATMENT OF CRUISING BLOOD DISEASES |
| CA2726537A1 (en) | 2008-06-06 | 2009-12-10 | University Health Network | 8-hydroxyquinoline derivatives for the treatment of hematological malignancies |
| WO2010000796A1 (en) * | 2008-07-02 | 2010-01-07 | Assistance Publique - Hôpitaux De Paris | A method for predicting clinical outcome of patients with non-small cell lung carcinoma |
| DK3091085T3 (da) | 2010-10-06 | 2019-05-06 | Inst Catalana Recerca Estudis Avancats | Fremgangsmåde til at designe en terapi mod brystcancermetastase |
| CA2826657A1 (en) | 2011-02-04 | 2012-08-09 | Bioarray Therapeutics, Inc. | Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment |
| EP2650682A1 (en) * | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| ES2906586T3 (es) | 2012-10-12 | 2022-04-19 | Inbiomotion Sl | Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata |
| WO2014140896A2 (es) | 2013-03-15 | 2014-09-18 | Fundacio Privada Institut De Recerca Biomedica | Metodo para el diagnostico, pronostico y tratamiento de la metastasis de un cancer |
| KR20150122731A (ko) * | 2013-03-15 | 2015-11-02 | 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) | 암 전이의 예후 및 치료 방법 |
| WO2014184679A2 (en) | 2013-03-15 | 2014-11-20 | Inbiomotion S.L. | Method for the prognosis and treatment of renal cell carcinoma metastasis |
| AU2014333513B2 (en) | 2013-10-09 | 2020-11-26 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer |
| JP6920062B2 (ja) | 2014-06-17 | 2021-08-18 | アイジェノミクス エセ．エレ． | 子宮内膜病変における幹細胞治療 |
| EP3229909B1 (en) | 2014-12-11 | 2020-10-14 | Inbiomotion S.L. | Binding members for human c-maf |
| MX2018014279A (es) | 2016-05-25 | 2019-07-08 | Inbiomotion Sl | Tratamiento terapeutico de cancer de mama con base en estado de c-maf. |
| US11654153B2 (en) | 2017-11-22 | 2023-05-23 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-MAF status |
-
2013
- 2013-06-06 BR BR112014030750A patent/BR112014030750A2/pt not_active Application Discontinuation
- 2013-06-06 AU AU2013273242A patent/AU2013273242B2/en active Active
- 2013-06-06 ES ES13766663T patent/ES2705237T3/es active Active
- 2013-06-06 DK DK13766663.2T patent/DK2859120T3/en active
- 2013-06-06 WO PCT/IB2013/001859 patent/WO2013182912A2/en not_active Ceased
- 2013-06-06 MX MX2014014802A patent/MX368513B/es active IP Right Grant
- 2013-06-06 JP JP2015515598A patent/JP6386450B2/ja active Active
- 2013-06-06 CN CN201380037529.4A patent/CN104603288B/zh active Active
- 2013-06-06 US US14/405,724 patent/US10006091B2/en active Active
- 2013-06-06 CA CA2875918A patent/CA2875918A1/en not_active Abandoned
- 2013-06-06 EP EP18206025.1A patent/EP3467124A1/en not_active Withdrawn
- 2013-06-06 TR TR2018/19859T patent/TR201819859T4/tr unknown
- 2013-06-06 KR KR1020147035982A patent/KR102226219B1/ko active Active
- 2013-06-06 EP EP13766663.2A patent/EP2859120B1/en active Active
-
2018
- 2018-05-21 US US15/984,629 patent/US11352673B2/en active Active
-
2019
- 2019-06-18 AU AU2019204269A patent/AU2019204269A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Meng et al. | Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients | |
| JP2016516403A5 (enExample) | ||
| Thomas et al. | Expression profiling of cervical cancers in I ndian women at different stages to identify gene signatures during progression of the disease | |
| Liu et al. | Keratin 17 activates AKT signalling and induces epithelial-mesenchymal transition in oesophageal squamous cell carcinoma | |
| JP2015520606A5 (enExample) | ||
| WO2013182912A4 (en) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | |
| Shames et al. | High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck | |
| Shi et al. | Genome-scale analysis identifies NEK2, DLGAP5 and ECT2 as promising diagnostic and prognostic biomarkers in human lung cancer | |
| JP2016539625A5 (enExample) | ||
| JP2016105731A5 (enExample) | ||
| JP5690588B2 (ja) | 肝細胞癌のサブタイプを決定し、肝癌幹細胞を検出するための方法 | |
| Al-Khanbashi et al. | Tissue and serum miRNA profile in locally advanced breast cancer (LABC) in response to neo-adjuvant chemotherapy (NAC) treatment | |
| Cui et al. | LncRNA FAM230B promotes gastric cancer growth and metastasis by regulating the miR-27a-5p/TOP2A axis | |
| Hung et al. | Up-regulation of microRNA-190b plays a role for decreased IGF-1 that induces insulin resistance in human hepatocellular carcinoma | |
| JP2013541339A5 (enExample) | ||
| JP2018078911A5 (enExample) | ||
| Sahay et al. | The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer | |
| JP2012522756A5 (enExample) | ||
| JP6931926B2 (ja) | 遺伝子発現プロファイル及び乳癌におけるその使用 | |
| Davidson et al. | Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions | |
| JP2008536480A5 (enExample) | ||
| EP3215635A1 (en) | Embryonic isoforms of gata6 and nkx2-1 for use in lung cancer diagnosis | |
| JP2014533960A5 (enExample) | ||
| Pan et al. | miR-566 functions as an oncogene and a potential biomarker for prognosis in renal cell carcinoma | |
| WO2010101916A1 (en) | Methods for predicting cancer response to egfr inhibitors |